We investigated early phenotypes caused by familial Alzheimer's disease (fAD) mutations in isogenic human iPSC-derived neurons. Analysis of neurons carrying fAD PS1 or APP mutations introduced using genome editing technology at the endogenous loci revealed that fAD mutant neurons had previously unreported defects in the recycling state of endocytosis and soma-to-axon transcytosis of APP and lipoproteins. The endocytosis reduction could be rescued through treatment with a b-secretase inhibitor. Our data suggest that accumulation of b-CTFs of APP, but not Ab, slow vesicle formation from an endocytic recycling compartment marked by the transcytotic GTPase Rab11. We confirm previous results that endocytosis is affected in AD and extend these to uncover a neuron-specific defect. Decreased lipoprotein endocytosis and transcytosis to the axon suggest that a neuron-specific impairment in endocytic axonal delivery of lipoproteins and other key materials might compromise synaptic maintenance in fAD.
INTRODUCTION
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder that affects more than 30 million people worldwide, including 11% of those over 65 years of age and 32% of those over 85 (Alzheimer's Association, 2014) . AD is characterized by progressive cerebral dysfunction, memory loss, synapse loss, and neuronal impairment leading to cell death. To date, there are no disease-modifying treatments that can cure or reduce the progression of AD. Genetically, AD is segmented into two populations: sporadic AD (sAD), where the underlying primary cause is not known, and rare autosomaldominant mutations causing familial AD (fAD) (Gatz et al., 2006) . The common pathological features of sAD and fAD patients are the accumulation of senile plaques, composed of aggregated amyloid-b (Ab), and neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau (Spires-Jones and Hyman, 2014) . Importantly, many experimental findings regarding AD have come from overexpression studies or studies of non-neuronal cells that lack the unique polarization and compartmentalization of neurons.
The amyloid cascade hypothesis of AD posits that extracellular Ab fragments of proteolytically processed amyloid precursor protein (APP) and intraneuronal tau accumulate abnormally in sAD and fAD. These accumulations are proposed to drive cellular stress, neurotoxicity, and, ultimately, synapse loss and neurodegeneration (Toyn and Ahlijanian, 2014) . Previous work also reported apparent defects in early endocytosis in post-mortem brains of AD patients (Cataldo et al., 2001; Ginsberg et al., 2010) . Complementary investigations in overexpression and non-neuronal cellular models also pointed to defects in early endocytosis and endocytic dysfunction driven not by Ab but, instead, by b C-terminal fragments (b-CTFs) of APP (von Bartheld, 2004; Cataldo et al., 2000; Ginsberg et al., 2010; Karch and Goate, 2015; Lee et al., 2010; Maxfield, 2014) . In addition, unbiased screens in non-neuronal cells consistently identified regulators of endocytic trafficking as key to normal levels of APP processing (Cataldo et al., 2000; Ginsberg et al., 2010; Treusch et al., 2011) . However, many of the key investigations did not utilize normal expression levels of AD-related proteins or did not fully examine sorting pathways in highly polarized neurons. Thus, although several important insights into the role of endocytosis in regulating APP processing and sorting have been obtained from various cell models, little is known about endocytosis-dependent trafficking in polarized human neurons with mutations expressed at normal levels.
We tested whether isogenic induced pluripotent stem cell (iPSC)-derived human neurons with fAD PS1 and APP mutations induced by genome editing mutagenesis (transcription activator-like effector nuclease [TALEN] and clustered regularly interspaced short palindromic repeats [CRISPR] (legend continued on next page) and transport phenotypes, beyond the known effects on APP processing, that could account for the development of fAD (von Bartheld, 2004; Cataldo et al., 2000; Ginsberg et al., 2010; Karch and Goate, 2015; Lee et al., 2010; Maxfield, 2014) . Human neurons expressing fAD mutant PS1 and APP at normal expression levels from the endogenous loci alter subcellular distribution and trafficking of APP and internalized lipoprotein, leading to elevated levels of APP in the soma and reduced levels in the axons. The redistribution of APP is accompanied by the concurrent accumulation of Rab11 endosomal vesicles in the neuronal soma and reduced Rab11 axonal staining, suggesting that the reduction in axonal APP and lipoproteins can be explained by reduced Rab11-dependent soma-to-axon transcytosis and defects in the recycling endosome (Ascañ o et al., 2009; von Bartheld, 2004; Buggia-Pré vot et al., 2014) . Knockdown of Rab11 also leads to reductions in APP axonal density and lipoprotein endocytosis and transcytosis. Our study reveals that a common early defect among fAD PS1 and APP mutations is APP b-CTF accumulation-induced impairment of a key neuron-specific traffic pathway, soma-to-axon transcytosis, caused by defects in the recycling endosome.
RESULTS
The PS1 DE9 Mutation Increases APP in the Soma of Human Neurons and Decreases APP in Axons PS1 has been reported to have a role in APP trafficking in primary neurons and in non-neuronal cell types (Burns et al., 2003; Cai et al., 2003; Gandy et al., 2007; Zhang et al., 2006) . PS1 knockout has been reported to increase cell surface APP (Leem et al., 2002) , whereas PS1 fAD mutations have been shown to delay APP arrival at the cell surface (Cai et al., 2003; Gandy et al., 2007) . To determine whether the PS1 DE9 mutation affects APP localization in human neurons, we generated purified neurons from isogenic iPSC lines from wild-type (PS1 WT/WT ) and lines heterozygous (PS1 WT/DE9 ) and homozygous (PS1 DE9/DE9 ) for the PS1 DE9 mutation (Woodruff et al., 2013) . We stained with an APP antibody that has minimal staining in cells from APP knockout mice (Guo et al., 2012; Weissmiller et al., 2015) . We found that PS1 WT/DE9 and PS1 DE9/DE9 neurons exhibited a modest but significant increase in intracellular APP staining in the cell body ( Figure 1A ). To determine whether APP was also increased on the surface of PS1
DE9
neurons, we stained unpermeabilized purified neurons with an N-terminal APP antibody that recognizes the extracellular portion of APP (22C11) ( Figure 1B ). We observed increased APP on the soma surface of PS1 DE9 neurons ( Figure 1B) . As a control, we also stained unpermeabilized neurons with a C-terminal antibody and observed minimal staining, as would be expected because the C terminus of APP would not be present on the cell surface ( Figure 1C ). We previously published that PS1 DE9 human neurons do not exhibit changes in total levels of full-length APP, although there are increases in the APP CTFs (Woodruff et al., 2013) . The increase in soma APP suggests that APP CTFs are accumulating in the soma of purified neurons and/or that APP is missorted, possibly at the expense of axonal APP. We therefore assessed APP staining in the axons of PS1 DE9 neurons. To ensure that we were quantifying staining in axons and not dendritic processes, we made use of microfluidic compartments, which separate axons from the bulk somatodendritic population (Figure 1E ; Niederst et al., 2015; Selfridge et al., 2015; Taylor et al., 2005) . Neurons grown in microfluidic devices extend long processes into the axonal space that do not stain for the somatodendritic marker Map2 and that do stain for the axonal marker neurofilament-H (SMI31) (Selfridge et al., 2015; Figure 1E; Figure S1A) . We observed that PS1 DE9 axons grown in microfluidic devices have decreased axonal APP puncta and APP punctum intensity ( Figure 1D ); this decrease is sensitive to PS1 DE9 gene dose.
To further characterize APP fragments that are present in axons, we also measured soluble APP (sAPP) fragments, sAPPa and sAPPb. To quantify secreted sAPP, we plated neurons in compartments and allowed them to extend their axons into the axonal space. We then performed a full medium change, kept the axons in fluidic isolation, and harvested media from the soma and axon sides. When we measured the sAPPa/sAPPb ratio from the soma side of the cultures, we observed no significant differences between PS1
WT/WT and PS1 DE9/DE9 genotypes ( Figure 1F ). Additionally, there were no significant differences in the total levels of sAPPa or sAPPb from the soma side ( Figure S1B ). However, when we quantified the sAPPa/sAPPb ratio from axons only, we observed a significant increase from the PS1 DE9/DE9 axons compared with PS1 WT/WT ( Figure 1F ). Upon quantification of the total levels of sAPPa and sAPPb, we determined that the ratio was increased in PS1 DE9/DE9 axons primarily because of a reduction in sAPPb ( Figure 1F ). To test whether the phenotypic differences we observed in PS1 DE9 neurons might be due to differences in neuronal subtypes in our cultures, we stained neurons of each genotype with the neuronal subtype markers gamma-aminobutyric acid (GABA), GAD65/67, and vesicular glutamate transporter (vGlut) ( Figure S1C ). We found no significant differences in the proportion of cells that stained positive for GABA, GAD65/67, or vGlut between different genotypes ( Figure S1C ).
Rab11 Distribution Is Altered in PS1 DE9 Neurons
There are at least two pathways by which APP can be delivered to the axon. The first is by direct delivery from the trans-Golgi network (TGN), and the second is by an indirect pathway where APP first arrives at the cell surface of the somatodendritic compartment and then undergoes endocytosis and sorting to the axon. The indirect pathway is a process known as transcytosis, and multiple cargos, including TrkA (Ascañ o et al., 2009 ) and L1/NgCAM (Anderson et al., 2005;  (F) sAPPa/b ratios in soma were not statistically different (p = 0.9614), but the ratio of axonally secreted sAPPa/b was increased in PS1 DE9/DE9 axons (p = 0.0199). See also Figure S1 . (legend continued on next page) Yap et al., 2008) , have been demonstrated to be sorted along this pathway in neurons. An endocytic regulator that functions at the intersection of the TGN and transcytotic pathways is the Rab GTPase Rab11 (Welz et al., 2014) . Rab11 has a well-established role in mediating the recycling of many receptors, including the transferrin receptor (Ullrich et al., 1996) , and low-density lipoprotein (LDL) receptors (Sakane et al., 2010; Takahashi et al., 2007) . In addition to its role in recycling, Rab11 has also been shown to mediate transcytosis in epithelial cells and neurons. Specifically in neurons, TrkA receptors undergo Rab11-dependent transcytosis to the axon (Ascañ o et al., 2009; Lazo et al., 2013) . Rab11 may also be involved in trafficking of BACE1 to the axon (Buggia-Pré vot et al., 2014) , colocalizes with some APP in axons (Niederst et al., 2015) , and was recently identified in an unbiased Rab GTPase screen in non-neuronal cells as a regulator of Ab and sAPPb production (Udayar et al., 2013) . Intriguingly, presenilins have also been reported to interact directly with Rab11 through their hydrophilic loop (Dumanchin et al., 1999) .
To determine whether Rab11 could be playing a role in the reduction of axonal APP in PS1 DE9 cells, we stained neurons with a Rab11 antibody and measured Rab11 in the somatodendritic and axonal compartments. The Rab11 staining was reminiscent of the altered APP distribution such that PS1
neurons exhibited increased soma Rab11 intensity, Rab11 puncta, and Rab11 punctum area ( Figure 2A ). In axons, both the PS1 WT/DE9 and PS1 DE9/DE9 genotypes had decreased Rab11 punctum density and punctum intensity ( Figure 2B ).
In support of a role of Rab11-dependent trafficking of APP to the axon, short hairpin RNA (shRNA)-mediated knockdown of Rab11 on the soma side of neurons grown in microfluidic devices resulted in an 40% reduction in APP axonal density ( Figure 2C ). In keeping with a transcytotic route of APP to the axon, somatodendritic inhibition of endocytosis with Dynasore led to reduced APP (25% less) and Rab11 (40% less) density in axons ( Figure 2D ). Previous publications have implicated alterations in early endosomes and lysosomes in PS1 knockout cells (Coen et al., 2012; Lee et al., 2010; Neely et al., 2011) . We therefore looked at the early endosome effector EEA1 and the lysosomal marker Lamp2 even though they are not thought to traffic substantially to axons (Wilson et al., 2000) . Despite evidence in the literature that early endosomes and lysosomes are dramatically affected in fAD and sAD, EEA1 and Lamp2 staining in PS1 DE9 neurons was not obviously different, suggesting that they are not playing an active role in sorting APP to the axon (Figures S2A and S2B).
The PS1 DE9 Mutation Decreases Endocytosis and
Transcytosis of APP and LDL Because we observed alterations in the subcellular distribution of both APP and Rab11 in PS1 DE9 neurons, we investigated whether endocytosis and/or transcytosis could account for the APP localization changes. To assess endocytosis of APP, we treated purified neurons with an N-terminal APP antibody (22C11) and allowed cells to internalize the antibody for 30 min, 2 hr, or 4 hr and fixed cells at each of those time points. We then stained with a secondary antibody and quantified the amount of APP endocytosis at each time point ( Figure 3A ). We observed a decrease in APP puncta in the PS1 DE9/DE9 genotype starting at 30 min compared with PS1 WT/WT , and this decrease was more prominent at both 2 and 4 hr ( Figure 3A) . The PS1 WT/DE9 genotype also exhibited decreased APP puncta compared with PS1 WT/WT at the 2-and 4-hr time points. As a control to confirm whether the APP antibody was being endocytosed uniquely via antigen binding, we performed an endocytosis assay with a non-specific antibody and found minimal uptake ( Figure S3A ). To assess whether this endocytosis defect was specific to APP or common to other cargo, we also measured the uptake of fluorescently labeled LDL at 30 min, 1 hr, 2 hr, and 4 hr ( Figure 3B ). Similar to what was observed with APP, LDL punctum intensity and LDL punctum density were reduced in PS1 WT/DE9 and PS1 DE9/DE9 neurons at 2 hr and 4 hr ( Figure 3B ). To test whether the differences observed were due to a non-specific defect in endocytosis, we also quantified the uptake of fluorescently labeled dextran as a marker of bulk endocytosis. We did not observe any significant differences in dextran endocytosis at any time point ( Figure 3C ). Additionally, we quantified endocytosis of fluorescently labeled transferrin, and, similar to dextran, we did not observe any significant differences ( Figures S3B and S3C ). We measured transcytosis of APP and LDL by growing neurons in microfluidic compartments. The axon side of the compartment was kept in fluidic isolation from the soma side, and APP antibody or labeled LDL was added only to the soma side. Transcytotic delivery of cargo from the soma to the axon is a relatively slow process because internalized cargo has to travel long distances (on the order of millimeters in cultured neurons). After 4 hr of endocytosis, cells were fixed, and we quantified the amount of anterogradely transcytosed APP by using an anti-mouse secondary antibody; fluorescent LDL was measured directly (Figures 3D and 3E ). We observed that both the PS1
WT/DE9 and PS1 DE9/DE9 genotypes exhibited decreased APP axonal density and APP intensity after 4 hr of transcytosis ( Figure 3D ). Similarly, LDL axonal density and intensity were also decreased in PS1 WT/DE9 and PS1 DE9/DE9 axons after 4 hr , p = 0.0024) on the soma side with the axons in fluidic isolation. All intensity comparisons were p < 0.0001. Axons that passed through the channels were imaged, and punctum densities and intensities were evaluated. Data represent the mean ± SEM of four PS1
WT/WT , three PS1
WT/DE9 , and four PS1 DE9/DE9 biological replicates per stain. Scale bar, 5 mm.
See also Figure S3 . 22C11), but the percent of 22C11 with Rab11 remained steady ( Figure S4A ).
PS1

DE9 Impairs Recycling of LRP1
The absence of a lipoprotein endocytic defect at early time points in PS1 DE9 neurons suggested that transcription, levels, degradation, or recycling of the LDL receptor may be driving the reduction in transcytosis. Although there are many potential LDL receptors, LRP1 was an attractive candidate because of its high expression in brain and neuronal samples (Zhang et al., 2014) . To determine whether transcription or degradation of LRP1 was affected in PS1 DE9 neurons, we treated purified human neurons with unlabeled LDL and harvested neurons for mRNA and protein. We did not observe differences in LRP1 mRNA or protein levels ( Figure 5A ) at baseline or after LDL treatment, suggesting that transcription, total levels, and degradation of LRP1 after LDL treatment are not playing a role in the reduced endocytosis of LDL. Although PS1 has been hypothesized to drive reduced degradation of proteins because of alterations in lysosomal pH (McBrayer and Nixon, 2013; Nixon and Yang, 2011), we did not observe changes in lysosomal pH in the PS1 DE9 neurons, as assessed by the two ratiometric pH probes LysoSensor yellow/blue dextran and fluorescein-Dextran-tetramethylrhodamine (Figure S5A ). In addition, degradation of full-length APP is not different in PS1 DE9/DE9 neurons treated with cycloheximide ( Figure S5B ) or when lysosome degradation is blocked with chloroquine.
To determine whether the amount of lipoprotein receptors at the somatodendritic surface are driving endocytosis defects at later time points, we measured the LDL receptor amount at baseline and after 4 hr of LDL treatment using two different methods. Purified neurons were incubated at 4 C with labeled LDL for 30 min and then fixed (0-h time point); this gives a measure of total LDL receptors at the cell surface ( Figure 5B ). Neurons were also incubated for 4 hr with unlabeled LDL and then brought to 4 C, unlabeled LDL was washed off, and then cells were incubated with labeled LDL followed by fixation. This gives a measure of LDL receptors at the surface after 4 hr of endocytosis ( Figure 5B ). Under these conditions, there were no differences in surface LDL punctum count in PS1 DE9/DE9 neurons compared with PS1 WT/WT neurons ( Figure 5B ). Because LDL could be binding non-specifically to surface proteins, we evaluated specific receptor populations by biotinylating the surface of neurons with a cleavable biotin and used streptavidin beads to pull down surface proteins before and after LDL treatment. Probing for LRP1 demonstrated that the surface levels of LRP1 at baseline were not significantly different between PS1
WT/WT and PS1
DE9/DE9
. However, after 4 hr of LDL treatment, LRP1 receptor levels trend to decrease in PS1 DE9/DE9 (p = 0.1293) (Figure 5C) . Thus, the decrease in LDL endocytosis we observed in PS1 DE9/DE9 neurons ( Figure 3B ) can be accounted for in part by the modest (50%) LRP1 reduction at the neuronal surface after 4 hr of LDL treatment.
LDL Endocytosis Defects in PS1
DE9 Neurons Are
Rescued by b-Secretase Inhibition
We demonstrated previously that the PS1 DE9 mutation impairs g-secretase activity and that APP CTFs accumulate in human PS1 DE9 neurons (Woodruff et al., 2013) . A previous study also demonstrated that g-secretase inhibition in mouse embryonic fibroblasts (MEFs) reduces LDL endocytosis (Tamboli et al., 2008) . To determine whether g-secretase activity or the b-CTF fragment might be responsible for the impaired LDL endocytosis in human neurons, we treated PS1 WT/WT neurons with b-and g-secretase inhibitors and measured LDL endocytosis ( Figures  6A and 6B) . Inhibition of g-secretase severely decreased LDL endocytosis at 4 hr, whereas b-secretase inhibition had no significant effect ( Figures 6A and 6B) . Treatment with both band g-secretase inhibitors caused a marked accumulation of a-CTFs while ablating b-CTFs ( Figure 6C ) but had no effect on LDL endocytosis at 4 hr ( Figure 6B ). These results suggest that the b-CTF, not a-CTF, of APP is responsible for impairing LDL endocytosis in DE9 neurons. To further test this possibility, we treated PS1 DE9 neurons with a b-secretase inhibitor and measured LDL endocytosis ( Figures 6A and 6D) . We observed that, upon treatment with a b-secretase inhibitor, PS1
DE9/DE9
neurons were rescued in the ability to endocytose LDL (Figure 6D) . Treatment of PS1 DE9/DE9 neurons with both b-and g-secretase inhibitors, which abolishes b-CTF and increases a-CTF, also rescued the LDL endocytosis defect (Figure 6D ), which suggests that accumulation of only the b-CTF is responsible for impaired LDL endocytosis. To test whether b-secretase inhibition could rescue the transcytosis defect we observed, we treated PS1 DE9/DE9 neurons grown in microfluidic compartments with a b-secretase inhibitor and then measured LDL transcytosis ( Figures 6E and 6F ). Similar to the endocytosis result, we also observed that b-secretase inhibition significantly increased the amount of transcytosed LDL in PS1 DE9/DE9 neurons ( Figure 6E ).
LDL Endocytosis Defects Are Common to fAD APP Mutations
Accumulation of APP b-CTFs is a phenotype shared by many APP and PS1 fAD mutations (Chang and Suh, 2005; Sinha and Lieberburg, 1999) . To assess whether other fAD mutations might share a common phenotype of impaired LDL endocytosis, we generated additional isogenic cell lines harboring either the APP V717F (APP V717F ) or APP Swedish (APP swe ) mutations (Sherrington et al., 1995) . In neurons homozygous for the APP V717F mutation, there was significantly reduced LDL endocytosis after 4 hr, and this defect was rescued by b-secretase inhibition ( Figures 7A and 7B ). Similar to both the PS1 DE9 and APP V717F mutations, neurons homozygous for the APP swe mutation also exhibited decreased LDL endocytosis ( Figures 7A and  7B) . In contrast to the other fAD mutations, b-secretase inhibition in the APP swe neurons did not rescue the LDL endocytosis defect ( Figures 7A and 7B) . However, mutant APP Swedish protein has been reported previously to decrease the potency of b-secretase inhibitors (Yamakawa et al., 2010) , which could explain why, in our study, b-secretase inhibition did not rescue the APP swe neurons. These findings demonstrate that the reduction in LDL endocytosis is not specific to the PS1 DE9 mutation but is a phenotype common to fAD APP mutations. Similar to PS1 DE9 axons, we also observed reduced basal levels of axonal APP and Rab11 densities and reduced endocytosis of 22C11 at 4 hr in APP V717F neurons ( Figure S6 ). Thus, endocytosis defects, and perhaps transcytosis defects, are common among at least one fAD PS1 mutation and two fAD APP mutations.
DISCUSSION
Here we demonstrate that, in human neurons with endogenous expression of fAD mutations induced with genome editing technology, increased b-CTF of APP alters the subcellular localization of APP and the distribution of Rab11 and decreases endocytosis and soma-to-axon transcytosis of LDL. LDL endocytosis and transcytosis defects are rescued by b-secretase inhibition in at least some of the fAD mutations. Our results show (B) Quantification of LDL punctum count per soma in 4-hr LDL-treated PS1 WT/WT neurons. Treatment with a g-secretase inhibitor (GSI) resulted in a decrease in LDL endocytosis in PS1 WT/WT neurons, whereas treatment with a b-secretase inhibitor (BSI) had no effect. Data represent the mean ± SEM of 12 PS1
WT/WT , 6 GSI 100 nM (p < 0.0001), 6 GSI 1mM (p < 0.0001), 12 BSI 4 mM (not significant [n.s.]), and 4 GSI 1 mM + BSI 4 mM (n.s) biological replicates. that impaired LDL endocytosis and transcytosis are present in multiple types of fAD mutations, ( Figure 7C ) and that together they define an apparent defect in the Rab11 recycling endosome. Epidemiologic evidence implicating cholesterol as a major player in AD also dovetails with these molecular and cellular findings (reviewed in Fonseca et al., 2010, and Wolozin, 2004) . We demonstrate that APP b-CTFs may cause impaired LDL uptake by reducing recycling of LRP1 receptors back to the cell surface. One possible mechanism is that b-CTFs bind to LRP1 (Kounnas et al., 1995; Pietrzik et al., 2002; Tamboli et al., 2008) , or other LDL receptors and retain LDL receptors in a Rab11-containing compartment until the b-CTF is cleaved by g-secretase. This would possibly explain why g-secretase inhibition impairs LDL uptake and why that defect can be rescued by b-secretase inhibition. The observation that basal Rab11 is reduced in axons of fAD mutant neurons suggests that a common constitutive recycling/transcytotic pathway is impaired and raises the possibility that modulating Rab11 activity could also rescue fAD phenotypes. Although we cannot rule out proteolysis of the 22C11 or labeled LDL probe following endocytosis as a possible explanation for the reduced transcytosis, our data are most consistent with the possibility reported in previous work that early endocytosis is affected (Cataldo et al., 2000) .
The finding that fAD neurons have defects in lipoprotein transcytosis is intriguing in light of previous work showing that neurons are dependent on the uptake of extracellular cholesterol from lipoprotein particles to perform functions such as axon elongation and synapse formation and maintenance (Barres and Smith, 2001; Lane-Donovan et al., 2014; Mauch et al., 2001; Nä gler et al., 2001; Pfrieger, 2003; Pierrot et al., 2013) . In fact, glia-derived cholesterol was reported to enhance synaptogenesis of the adult rat CNS Nä gler et al., 2001) , suggesting that a defect in endocytosis and transcytosis of extracellularly derived cholesterol could have long-term functional consequences leading to impaired neurotransmitter release and synaptic function. For instance, many studies of APOE function have focused on its potential role in mediating Ab clearance, but APOE has also been identified as the major lipoprotein carrier in the brain, and the e4 allele is less efficient in transporting brain cholesterol (Liu et al., 2013) . Interestingly, post-mortem studies comparing sAD patients to age-matched controls found that brain cholesterol levels are reduced in the areas of learning and memory, the hippocampus and cortex (Svennerholm and Gottfries, 1994) .
Previous work implicated early endosome dysfunction in sAD and some forms of fAD (Cataldo et al., 2001; Ginsberg et al., 2010) . In contrast to previous studies, we report abnormalities in a Rab11-marked recycling endosome in fAD mutations, which is consistent with previous work on transcytosis that identified Rab11 as an endocytic regulator with a unique role in polarized cells, including neurons (Ascañ o et al., 2009; Buggia-Pré vot et al., 2014; Welz et al., 2014) . Thus, we describe a defect in a neuron-specific pathway that could contribute to the reported early endosomal defects and could produce AD pathology. In contrast, other recent findings have suggested that lysosomal pathology is the major driver of pathology in PS1 fAD mutations (Lee et al., 2010 (Lee et al., , 2015 . Our data suggest that dysfunction in endosomal sorting could drive changes in lysosomal function rather than an original defect in the lysosome that drives such changes (Peric and Annaert, 2015) .
We thus propose that transcytotic trafficking defects could be at the root of many types of fAD and, potentially, sAD. In fact, endocytic trafficking changes have been reported for APOE4 relative to APOE3 and 2 (Chen et al., 2010) . These types of defects could lead to previously reported axonal amyloid-dependent and -independent transport defects Stokin et al., 2008; Vossel et al., 2015) . Similarly, many fAD mutations thought to act solely by changing Ab production may, in fact, also act by changing sorting and trafficking signals in b-CTF of APP, leading to changes in constituents of axonal vesicles derived by transcytotic trafficking of lipoproteins and other key synaptic constituents. Although it may seem counter-intuitive that cleavage of b-CTF is needed to generate axonal vesicles containing b-CTF or full-length APP, we suggest that b-CTF cleavage happens in the portion of the recycling endosome that remains in the soma and that buds off axonal vesicles with APP, lipoproteins, and other components ( Figure 7C ). Finally, we note that the defects we report occur in the absence of overexpression of any of the proteins involved and, thus, may accurately reflect the earliest changes from normal behavior generated by fAD.
EXPERIMENTAL PROCEDURES
Statistical Methods
Statistics were performed using GraphPad Prism. Normality for each dataset was assessed using D'Agostino-Pearson test. When data were normally distributed, a two-way ANOVA with a post hoc Tukey test was used to compare genotypes. For precise p value comparisons, a multiple t test was done after ANOVA calculations. Most immunofluorescence data were nonnormally distributed, and a nonparametric Kruskal-Wallis test with Dunn's multiple comparison was used to compare genotype medians. Data are depicted with bar graphs of the mean ± SEM of all values in an experiment or boxplots where the median is depicted with a line, and whiskers indicate the Tukey distribution as determined by GraphPad Prism.
Microfluidic Compartments
Microfluidic compartments were made in-house as described previously (Niederst et al., 2015) . Briefly, Sylgard 182 (Ellsworth Adhesives) was used to mold devices. When cured, the devices were cut and then washed with isopropanol, water, and 70% ethanol. The devices were plasma-treated and mounted onto glass coverslips. The mounted device was this coated with poly-ornithine/ laminin (PO/L) as described above.
sAPP Measurements sAPP was measured from conditioned media from microfluidic compartments from the soma side (contained soma, axons, dendrites) and the axon side (axons only) 48 hr after a full medium change in which the axons were kept in fluidic isolation. sAPP was measured using the sAPPa/sAPPb human kit (Meso Scale Discovery). The kit has a sensitivity down to 120 pg/mL for sAPPa and 52 pg/mL for sAPPb, and all measurements were in the linear range.
Immunofluorescence Purified neurons were grown in 384-well imaging plates at a density of 25,000 cells/well for 7-9 days after sorting. Neurons were fixed in 4% paraformaldehyde and PBS for 30 min at 37 C, permeabilized with 0.1% Triton X-100, and blocked (10% donkey serum, 3% BSA, and 0.1% Triton X-100 in PBS). For surface labeling experiments, neurons were not permeabilized. For compartment experiments, polydimethylsiloxane (PDMS) microfluidic devices were plasma-bonded directly onto glass coverslips (Niederst et al., 2015) . Neurons were seeded at a density of one to three million cells per compartment and grown for 7-10 days (until axons passed through the channels). Compartments were then fixed as above and imaged. The antibodies used for immunofluorescence experiments were anti-Rab11 (1:1,000, Life Technologies, 71-5300), anti-APP Y188 (1:200, Abcam, ab32136), anti-APP 22C11 (1:100, EMD Millipore, MAB348), anti-EEA1 (1:100, BD 610457), anti-NF-H (1:1,000, BioLegend, SMI-31r), and anti-Map2 (1:500, ab5392 
Endocytosis and Transcytosis
For constitutive uptake endocytosis assays, neurons were incubated with LDL-boron-dipyrromethene (BODIPY) (20 mg/mL, Invitrogen L3483) or Dextran-tetramethylrhodamine (TMR), molecular weight (MW) 10,000 (250 mg/mL, Invitrogen, D1817) at 37 C for the indicated times, fixed, and imaged. For all fixed endocytosis assays, a custom ImageJ program was used to identify Map2-positive soma and automatically generate regions of interest (ROIs) corresponding to soma. Mean intensity and punctum count per soma were determined and averaged across images and experiments. All endocytosis assays were repeated at least three times. In experiments where secretase inhibitors were used, cells were treated with the inhibitor 24 hr prior to the experiment and kept in the presence of the inhibitor for the duration of the experiment. Compound E (GSI, EMD Chemicals) was used at 200 nM in endocytosis assays and at 100 nM and 1 mM for western blotting. bIV inhibitor (b Inh, Millipore) was used at 4 mM.
For transcytosis experiments, neurons were grown in compartments and treated on the soma side with LDL-BODIPY (20 mg/mL), LDL-DiI (1,1'dioctadecyl-3,3,3',3-Tetramethyllindocarbocycanine Percholorate) (12.5 mg/mL), or mouse anti-22C11 (1:100) for 4 hr with axons in fluidic isolation. Axonal punctum analysis was done as described previously (Szpankowski et al., 2012) . Axons were imaged at 3100, and a custom Gaussian-fitting colocalization package in MATLAB (MathWorks) was used to calculate axonal density, punctum intensity, and percent colocalization per axon. All iPSCs were generated following informed consent and Institutional Review Board approval.
Surface Biotinylation Assay
Neuronal medium was changed to warm fresh medium or medium supplanted with 12.5 mg/mL of unlabeled LDL for 4 hr. At the end of the incubation, neurons were washed twice with ice-cold PBS and then incubated at 4 C with 2 mM EZ-Link Sulfo-NHS-SS-Biotin (Life Technologies) in PBS for 30 min. Cells were then lysed in equal volumes of radioimmunoprecipatation assay lysis (RIPA) buffer. For pull-down experiments, 200 mg of harvested protein at 0.5 mg/mL was incubated with 50 mL of pre-washed Pierce streptavidin magnetic beads (Life Technologies, 88817) overnight at 4 C. The next day, beads were washed to remove residual, unbound proteins, and biotinylated proteins were released from the streptavidin beads by boiling samples in loading buffer at 100 C. Western blots were run with 5% of input, 5% of supernatant, and 50% of pull-down. Quantification of recycling was determined based on input signal (pull-down/input).
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